|
US4780461A
(en)
|
1983-06-15 |
1988-10-25 |
Schering Aktiengesellschaft |
13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
|
|
DE3321826A1
(de)
|
1983-06-15 |
1984-12-20 |
Schering AG, 1000 Berlin und 4709 Bergkamen |
13(alpha)-alkylgonane, deren herstellung und diese enthaltende pharmazeutische praeparate
|
|
ES8502612A1
(es)
|
1983-06-15 |
1985-02-01 |
Schering Ag |
Procedimiento para la preparacion de 13a-alquilgonanos
|
|
US4742000A
(en)
|
1986-05-02 |
1988-05-03 |
University Of Chicago |
Antibody to human progesterone receptor and diagnostic materials and methods
|
|
DE3630030A1
(de)
|
1986-09-01 |
1988-03-03 |
Schering Ag |
13(alpha)-alkylgonan-(delta)(pfeil hoch)9(pfeil hoch)(pfeil hoch)((pfeil hoch)(pfeil hoch)1(pfeil hoch)1(pfeil hoch))(pfeil hoch)-5,10-epoxide
|
|
US4774236A
(en)
|
1986-09-17 |
1988-09-27 |
Research Triangle Institute |
17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
|
|
IE60780B1
(en)
|
1987-01-23 |
1994-08-10 |
Akzo Nv |
New 11-aryl steroid derivatives
|
|
DE3822770A1
(de)
|
1988-07-01 |
1990-01-04 |
Schering Ag |
13-alkyl-11ss-phenylgonane
|
|
US5283190A
(en)
|
1989-07-31 |
1994-02-01 |
Traish Adbulmaged M |
Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use
|
|
DE4008584A1
(de)
|
1990-03-15 |
1991-09-26 |
Schering Ag |
Verfahren zur herstellung von zwischenprodukten fuer die antigestagensynthese (onapristonsynthese)
|
|
US5141961A
(en)
|
1991-06-27 |
1992-08-25 |
Richrdson-Vicks Inc. |
Process for solubilizing difficulty soluble pharmaceutical actives
|
|
MX9301121A
(es)
|
1992-03-02 |
1993-09-01 |
Schering Ag |
Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
|
|
CN1053450C
(zh)
|
1992-11-19 |
2000-06-14 |
北京第三制药厂 |
17位取代11β－取代芳香基－4,9－雌甾二烯类化合物的全合成法
|
|
DE4332283A1
(de)
|
1993-09-20 |
1995-04-13 |
Jenapharm Gmbh |
Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
|
|
AU707235B2
(en)
*
|
1994-10-24 |
1999-07-08 |
Schering Aktiengesellschaft |
Competitive progesterone antagonists for demand-oriented female birth control
|
|
US5759577A
(en)
|
1995-01-17 |
1998-06-02 |
American Home Products Corporation |
Controlled release of steroids from sugar coatings
|
|
US6900193B1
(en)
|
1996-05-01 |
2005-05-31 |
The United States Of America As Represented By The Department Of Health And Human Services |
Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
|
|
IL122740A
(en)
|
1997-01-15 |
2003-09-17 |
Akzo Nobel Nv |
16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
|
|
US5962444A
(en)
|
1998-05-29 |
1999-10-05 |
Research Triangle Institute |
17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
|
|
US6537584B1
(en)
|
1999-11-12 |
2003-03-25 |
Macromed, Inc. |
Polymer blends that swell in an acidic environment and deswell in a basic environment
|
|
CN109395082A
(zh)
|
2000-05-19 |
2019-03-01 |
杰南技术公司 |
用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
|
|
US6750015B2
(en)
|
2000-06-28 |
2004-06-15 |
Kathryn B. Horwitz |
Progesterone receptor-regulated gene expression and methods related thereto
|
|
UY26966A1
(es)
|
2000-10-18 |
2002-06-20 |
Schering Ag |
Uso de antiprogestinas para la inducción de apoptosis en una célula
|
|
US7381976B2
(en)
|
2001-03-13 |
2008-06-03 |
Triton Thalassic Technologies, Inc. |
Monochromatic fluid treatment systems
|
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
|
US7105642B2
(en)
|
2001-08-03 |
2006-09-12 |
Cell Signalling Technology, Inc. |
Monoclonal antibodies specific for phosphorylated estrogen receptor alpha (Ser118) and uses thereof
|
|
US20040121304A1
(en)
|
2001-12-21 |
2004-06-24 |
Ulrike Fuhrmann |
Method for screening for progesterone receptor isoform-specific ligands and for tissue-selective progesterone receptor ligands
|
|
CA2516319C
(en)
|
2003-02-28 |
2012-09-18 |
The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services |
Method for preparing 17.alpha.-acetoxy-11.beta.-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
|
|
US20040265371A1
(en)
|
2003-06-25 |
2004-12-30 |
Looney Dwayne Lee |
Hemostatic devices and methods of making same
|
|
US7247625B2
(en)
*
|
2003-10-09 |
2007-07-24 |
Wyeth |
6-amino-1,4-dihydro-benzo[d][1,3] oxazin-2-ones and analogs useful as progesterone receptor modulators
|
|
DK1768625T3
(da)
|
2004-07-09 |
2011-05-09 |
Population Council Inc |
Sammensætninger med vedvarende frigørelse indeholdende progesteron-receptormodulatorer
|
|
KR20070061893A
(ko)
|
2004-09-22 |
2007-06-14 |
트리패스 이미징, 인코포레이티드 |
유방암 예후를 평가하기 위한 방법 및 조성물
|
|
WO2006111856A1
(en)
|
2005-04-20 |
2006-10-26 |
Pfizer Limited |
Pyrazole derivatives as progesterone receptor antagonists
|
|
JP2009519710A
(ja)
|
2005-12-16 |
2009-05-21 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
遺伝子発現調節エレメントのハイスループットでの特徴付けのための機能性アレイ
|
|
US20070167971A1
(en)
|
2006-01-17 |
2007-07-19 |
Raymond Huey |
Devices and methods for promoting the formation of blood clots in esophageal varices
|
|
US20070166372A1
(en)
|
2006-01-19 |
2007-07-19 |
Mai De Ltd. |
Preparation of solid coprecipitates of amorphous valsartan
|
|
DK1989217T5
(da)
|
2006-02-17 |
2013-01-14 |
Janssen Pharmaceutica Nv |
11-Phospor-steroidderivater, der er anvendelige som progesteronreceptormodulatorer
|
|
DE102006054535A1
(de)
|
2006-11-15 |
2008-05-21 |
Bayer Schering Pharma Aktiengesellschaft |
Progesteronrezeptorantagonisten
|
|
WO2008128783A2
(en)
|
2007-04-24 |
2008-10-30 |
Dsm Ip Assets B.V. |
Photochemical process for the preparation of a previtamin d
|
|
CA2596204C
(en)
|
2007-08-07 |
2019-02-26 |
Historx, Inc. |
Method and system for determining an optimal dilution of a reagent
|
|
WO2009025759A1
(en)
|
2007-08-17 |
2009-02-26 |
Progenics Pharmaceuticals (Nevada), Inc. |
Tight junction proteins associated with infection and entry of hepatitis c virus (hcv), methods and uses thereof
|
|
HUE027696T2
(en)
*
|
2007-10-12 |
2016-10-28 |
Novartis Ag |
Preparations containing sphingosine-1-phosphate (S1P) receptor modulators
|
|
EP2075246A1
(en)
|
2007-12-27 |
2009-07-01 |
M. J. Institute of Research |
A process for preparation of amorphous form of atorvastatin hemi-calcium salt
|
|
CA2712005C
(en)
|
2008-02-05 |
2014-04-15 |
Harbor Biosciences, Inc. |
Pharmaceutical solid state forms
|
|
TWI539953B
(zh)
|
2008-04-28 |
2016-07-01 |
瑞波若斯治療學公司 |
用於治療乳癌之組成物和方法
|
|
TW201002736A
(en)
|
2008-04-28 |
2010-01-16 |
Repros Therapeutics Inc |
Compositions and methods for treating progesterone-dependent conditions
|
|
US8744695B2
(en)
|
2009-03-27 |
2014-06-03 |
Komatsu Ltd. |
Fuel consumption saving control device for work vehicle and fuel consumption saving method for work vehicle
|
|
WO2010126590A1
(en)
|
2009-04-27 |
2010-11-04 |
Cold Spring Harbor Laboratory |
Ptp1b inhibitors
|
|
US20110003753A1
(en)
|
2009-06-01 |
2011-01-06 |
Samuel Waxman Cancer Research Foundation |
COMPOSITIONS AND METHODS FOR DISRUPTING THE FUNCTION OF THE TRANSCRIPTIONAL REPRESSOR COMPONENT Sin3A-PAH2 DOMAIN TO INDUCE DIFFERENTIATION AND GROWTH INHIBITION IN BREAST CANCER
|
|
WO2011008172A1
(en)
|
2009-07-15 |
2011-01-20 |
S*Bio Pte Ltd |
9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt
|
|
US20110293511A1
(en)
*
|
2009-09-29 |
2011-12-01 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
US8261855B2
(en)
*
|
2009-11-11 |
2012-09-11 |
Flanders Electric, Ltd. |
Methods and systems for drilling boreholes
|
|
EP2515942B1
(en)
|
2009-12-15 |
2020-02-12 |
Pfizer Inc. |
Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
|
|
JP5894143B2
(ja)
*
|
2010-03-22 |
2016-03-23 |
リプロス セラピューティクス インコーポレイテッド |
抗黄体ホルモンの無毒送達のための組成物および方法
|
|
CA2817256A1
(en)
|
2010-11-12 |
2012-05-18 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
EP2651400B2
(en)
|
2010-12-16 |
2023-01-18 |
Amgen (Europe) GmbH |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
|
CA2822462A1
(en)
|
2010-12-20 |
2012-06-28 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
|
WO2012122514A1
(en)
|
2011-03-09 |
2012-09-13 |
Centrose, Llc |
Extracellular targeted drug conjugates
|
|
BR112013023277A2
(pt)
*
|
2011-03-11 |
2017-06-27 |
Celgene Corp |
métodos de tratamento de câncer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidibna-2,6-diona
|
|
ES2656988T3
(es)
|
2011-04-15 |
2018-03-01 |
J-Pharma Co., Ltd. |
Biomarcador para el cáncer de mama
|
|
DK2707390T3
(en)
|
2011-05-13 |
2016-02-29 |
Ganymed Pharmaceuticals Ag |
ANTIBODIES TO TREAT CANCER EXPRESSING CLAUDIN 6
|
|
US20130029953A1
(en)
*
|
2011-07-28 |
2013-01-31 |
Klaus Nickisch |
Progesterone antagonists
|
|
PH12014500683A1
(en)
|
2011-10-04 |
2014-05-12 |
Invivis Pharmaceuticals Inc |
Methods and systems for identfying and treating anti-progestin sensitive tumors
|
|
WO2013086379A2
(en)
|
2011-12-08 |
2013-06-13 |
Fundacion Sales |
Methods and compositions for treating antiprogestin-resistant cancers
|
|
US20130338016A1
(en)
|
2012-04-17 |
2013-12-19 |
Vala Sciences, Inc. |
Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis
|
|
HK1208057A1
(en)
|
2012-04-27 |
2016-02-19 |
Regents Of The University Of Minnesota |
Breast cancer prognosis, prediction of progesterone receptor subtype and prediction of response to antiprogestin treatment based on gene expression
|
|
EP2877210A4
(en)
|
2012-07-24 |
2016-06-29 |
Cedars Sinai Medical Center |
A NEW METHOD FOR DETECTING THE RESISTANCE TO CHEMOTHERAPY IN PATIENTS WITH LUNG CANCER
|
|
WO2014093918A1
(en)
|
2012-12-13 |
2014-06-19 |
Warsaw Orthopedic, Inc. |
Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury
|
|
JP2016512526A
(ja)
|
2013-03-12 |
2016-04-28 |
アルノ セラピューティクスＡｒｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ |
オナプリストン多形体及び使用方法
|
|
US20140363425A1
(en)
|
2013-03-13 |
2014-12-11 |
J. Dinny Graham |
Systems and methods for identifying cancers having activated progesterone receptors
|
|
US9096641B2
(en)
|
2013-06-05 |
2015-08-04 |
Evestra, Inc. |
Imidazolyl progesterone antagonists
|
|
CN103483449A
(zh)
|
2013-08-20 |
2014-01-01 |
东北农业大学 |
两种scFv抗体、其编码基因及其在制备治疗或预防鸡传染性法氏囊病制剂中的应用
|
|
US20150285803A1
(en)
|
2014-04-08 |
2015-10-08 |
Invivis Pharmaceuticals Inc. |
Systems and methods for identifying progesterone receptor subtypes
|
|
MX391191B
(es)
|
2014-11-17 |
2025-03-21 |
Context Biopharma Inc |
Composiciones de liberación extendida de onapristona y métodos.
|
|
CA2981173C
(en)
|
2015-03-23 |
2024-01-02 |
Evestra, Inc. |
Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
|
|
WO2017053793A1
(en)
|
2015-09-25 |
2017-03-30 |
Arno Therapeutics, Inc. |
Methods of making onapristone intermediates
|
|
MX2018007154A
(es)
|
2015-12-15 |
2019-01-10 |
Context Biopharma Inc |
Composiciones de onapristona amorfa y metodos para hacer las mismas.
|
|
JP2019513706A
(ja)
|
2016-03-21 |
2019-05-30 |
コンテキスト・バイオファーマ・インコーポレイテッド |
オナプリストン代謝物質組成物及び方法
|
|
CA3022961A1
(en)
|
2016-05-02 |
2017-11-09 |
Tetragenetics, Inc. |
Anti-kv1.3 antibodies, and methods of production and use thereof
|
|
WO2018067198A1
(en)
|
2016-10-03 |
2018-04-12 |
The Regents Of The University Of California |
Inhibitory antibodies and methods of use thereof
|